Improved oral nutraceutical-based intervention for the management of obesity: pterostilbene-loaded chitosan nanoparticles.

Abstract

Aim: To formulate and assess the oral anti-obesity effect of polymeric-based pterostilbene (PS)-loaded nanoparticles. Methods: Pterostilbene-hydroxypropyl β-cyclodextrin inclusion complex loaded in chitosan nanoparticles (PS/HPβCD-NPs) were prepared and characterized in vitro. Cytotoxicity, pharmacokinetics and anti-obesity effects were assessed on Caco-2 cell line and high-fat-diet-induced obesity rat model, respectively. In vivo assessment included histological examination, protein and gene expression of obesity biomarkers in adipose tissues. Results: Safe PS/HPβCD-NPs were successfully prepared with improved bioavailability compared with free PS. PS/HPβCD-NPs showed an improved anti-obesity effect, as supported by histological examination, lipid profile, UCP1 gene expression and protein expression of SIRT1, COX2, IL-6 and leptin. Conclusion: Orally administered PS nanoparticles represent a new and promising anti-obesity strategy owing to the sustainable weight loss and minimal side effects; this may be of great socio-economic impact.

• Authors: Lamia A Heikal, Amal H El-Kamel, Radwa A Mehanna, Hoda M Khalifa, Passainte S Hassaan
• Journal: Nanomedicine (London, England) (Nanomedicine (Lond)) Vol. 17 Issue 15 Pg. 1055-1075 (06 2022) ISSN: 1748-6963 [Electronic] England
• PMID: 36066036 (Publication Type: Journal Article)

Chemical References

• 2-Hydroxypropyl-beta-cyclodextrin
• 3,5-dimethoxy-4'-hydroxystilbene
• Chitosan
• Cyclooxygenase 2
• Interleukin-6
• Leptin
• Lipids
• pterostilbene
• Sirtuin 1

Topics

• Animals
• Rats
• 2-Hydroxypropyl-beta-cyclodextrin (therapeutic use)
• Caco-2 Cells
• Chitosan
• Cyclooxygenase 2
• Dietary Supplements
• Interleukin-6
• Leptin (genetics, therapeutic use)
• Lipids (therapeutic use)
• Nanoparticles
• Obesity (drug therapy)
• Sirtuin 1 (therapeutic use)